DOCSLIB.ORG

Antiseptic Solution Antiseptic Solution

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antiseptic Solution Antiseptic Solution Caution: For External Animal Use Only Description: Surface Wounds: This product is not to be used in animals intended for use as food for humans or other animals. The active ingredients in F10 ® brand Antiseptic solution are Benzalkonium " For wound irrigation flush as necessary. For skin decontamination apply as a chloride and Polyhexanide. Benzalkonium chloride is a biocide of the wash or spray and allow to air dry. Use of this product is prohibited in dogs, cats, and horses and in food-producing species such as quaternary ammonium group. Its chemical name is: N-Alkyl-N-benzyl-N,N- cattle, pigs, chickens, turkeys, rabbits, deer, ducks, pigeons, and turtles. dimethylammonium chloride. Polyhexanide is a cationic biocide. Its chemical Contraindications: name is: Poly (hexamethylene biguanide hydrochloride). Each mL of F10 ® Do not use with soaps or other chemicals brand Antiseptic Solution contains 54.0 mg of benzalkonium chloride and 4.0 mg of polyhexanide. Warnings: Not for use in humans. Keep out of reach of children. Indications: If accidentally ingested, do not induce vomiting. Give milk or water to drink. For the treatment and control of upper and lower respiratory tract disease If accidental eye contact, hold eye open and rinse with water for 10 minutes. associated with bacterial, fungal, or viral organisms susceptible to Seek medical help if necessary. benzalkonium chloride and polyhexanide in raptors, pet birds, captive small mammals, and captive reptiles. Effectiveness: The active ingredients Benzalkonium chloride and Polyhexanide act on the cell AntiseAntisepticptic For use as a topical antiseptic for surface wounds on raptors, pet birds, captive membrane causing it to rupture, resulting in the loss of essential cell small mammals, captive reptiles, and captive exotic/zoo mammals. components. Additionally, non-toxic ampholytic surfactants and sequesterants in the drug formulation aid in the penetration of the cell or spore wall. Examples Use only when there is a reasonable certainty that the treated animal will not be of clinical cases successfully treated with F10® brand Antiseptic Solution consumed by humans or food-producing animals. include upper respiratory tract disease associated with Pseudomonas spp. and SolutionSolution Dosage and Administration: Aspergillus spp. in birds, upper respiratory tract disease associated with Dilute the concentrate 1:250 with normal saline solution prior to use. Pasteurella spp., Pseudomonas spp., Aspergillus spp. and Mycoplasma spp. in small mammals, acute pneumonia and aspirational pneumonia in neonatal Nebulization: mammals, and upper and lower respiratory tract disease associated with Benzalkonium chloride and Polyhexanide topical solution " To Nebulize the glottis, trachea, lungs and air sacs for individual birds, reptiles Proteus mirabillis, Pseudomonas aeruginosa, Aeromonas spp. and and small mammals use a chamber connected to a nebulizing unit capable of Mycoplasma spp. in reptiles. All resulted in positive outcomes. producing a particle size smaller than 5μm but which allows the resulting “fog” to build-up inside the chamber within 5 minutes and continue for 20 to 40 To obtain product information, including Material minutes. Repeat 2 times a day for 2 to 4 weeks (up to 8 weeks in severe Safety Data Sheet (MSDS) e-mail:[email protected] cases) until the signs of illness resolve. In raptors, withhold food for 3 hours after nebulization as crop emptying may be delayed. Manufactured by: " For larger animals or groups of small animals, place them in a suitable sized Health and Hygiene (Pty) Ltd enclosed room in which a standing fog can be achieved in 5 minutes using a Cnr. Leader & Hoefsmid Streets, Stormill Ext. 10 portable electrical atomizer/fogger or a static pressure system capable of South Africa producing a particle size of ± 10 to 12μm. Repeat 2 times a day for 2 to 4 Tel: +27 11 474 1668 weeks (up to 8 weeks in severe cases) until the signs of illness resolve. www.healthandhygiene.co.za A broad spectrum topical antiseptic solution Nasal and Sinus Flushing: To report a suspected adverse reaction " To remove accumulated mucous and inflammatory material in the upper e-mail:[email protected] respiratory tract, syringe into the nasal and sinus cavities (consisting of the Adverse reactions may also be reported to external nares, operculum, nasal concha, infraorbital sinus and choanal slit) the FDA/CVM at 1-888-FDA-VETS or with the animal’s head down and mouth open to avoid aspiration and allow http://www.fda.gov/AnimalVeterinary/SafetyHealth NOT APPROVED BY THE FDA drainage out of the oral cavity. This treatment should be repeated daily for 10- Legally marketed as an FDA Indexed Product under MIF 900-007. Extra-label use is prohibited. 14 days until the signs of illness resolve. It is a violation of Federal law to use this product in a manner other than as directed on the labeling. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. 6 009673 133057 LOT NO: EXP. DATE: Store between 15 - 30ºC (59º to 86º F) in dry conditions 200ml Label Revision: Dec. 2014-8 Caution: For External Animal Use Only Description: Surface Wounds: This product is not to be used in animals intended for use as food for humans or other animals. The active ingredients in F10 ® brand Antiseptic solution are Benzalkonium " For wound irrigation flush as necessary. For skin decontamination apply as a Use of this product is prohibited in dogs, cats, and horses and in food-producing species such as chloride and Polyhexanide. Benzalkonium chloride is a biocide of the wash or spray and allow to air dry. quaternary ammonium group. Its chemical name is: N-Alkyl-N-benzyl-N,N- cattle, pigs, chickens, turkeys, rabbits, deer, ducks, pigeons, and turtles. dimethylammonium chloride. Polyhexanide is a cationic biocide. Its chemical Contraindications: Do not use with soaps or other chemicals name is: Poly (hexamethylene biguanide hydrochloride). Each mL of F10 ® brand Antiseptic Solution contains 0.22 mg of benzalkonium chloride and 0.02 Warnings: mg of polyhexanide. Not for use in humans. Keep out of reach of children. If accidentally ingested, do not induce vomiting. Give milk or water to drink. Indications: If accidental eye contact, hold eye open and rinse with water for 10 minutes. For the treatment and control of upper and lower respiratory tract disease Seek medical help if necessary. associated with bacterial, fungal, or viral organisms susceptible to benzalkonium chloride and polyhexanide in raptors, pet birds, captive small Effectiveness: mammals, and captive reptiles. The active ingredients Benzalkonium chloride and Polyhexanide act on the cell AntiseAntisepticptic membrane causing it to rupture, resulting in the loss of essential cell For use as a topical antiseptic for surface wounds on raptors, pet birds, captive components. Additionally, non-toxic ampholytic surfactants and sequesterants small mammals, captive reptiles, and captive exotic/zoo mammals. in the drug formulation aid in the penetration of the cell or spore wall. Examples of clinical cases successfully treated with F10® brand Antiseptic Solution Use only when there is a reasonable certainty that the treated animal will not be include upper respiratory tract disease associated with Pseudomonas spp. and SolutionSolution consumed by humans or food-producing animals. Aspergillus spp. in birds, upper respiratory tract disease associated with Pasteurella spp., Pseudomonas spp., Aspergillus spp. and Mycoplasma spp. in Dosage and Administration: This is a Ready to Use solution small mammals, acute pneumonia and aspirational pneumonia in neonatal mammals, and upper and lower respiratory tract disease associated with Benzalkonium chloride and Polyhexanide topical solution Nebulization: Proteus mirabillis, Pseudomonas aeruginosa, Aeromonas spp. and " To nebulize the glottis, trachea, lungs and air sacs for individual birds, reptiles Mycoplasma spp. in reptiles. All resulted in positive outcomes. and small mammals use a chamber connected to a nebulizing unit capable of producing a particle size smaller than 5μm but which allows the resulting “fog” To obtain product information, including Material to build-up inside the chamber within 5 minutes and continue for 20 to 40 Safety Data Sheet (MSDS) e-mail:[email protected] minutes. Repeat 2 times a day for 2 to 4 weeks (up to 8 weeks in severe cases) until the signs of illness resolve. In raptors, withhold food for 3 hours Manufactured by: after nebulization as crop emptying may be delayed. Health and Hygiene (Pty) Ltd " For larger animals or groups of small animals, place them in a suitable sized Cnr. Leader & Hoefsmid Streets, Stormill Ext. 10 enclosed room in which a standing fog can be achieved in 5 minutes using a South Africa portable electrical atomizer/fogger or a static pressure system capable of Tel: +27 11 474 1668 producing a particle size of ± 10 to 12μm. Repeat 2 times a day for 2 to 4 www.healthandhygiene.co.za weeks (up to 8 weeks in severe cases) until the signs of illness resolve. A broad spectrum topical antiseptic solution To report a suspected adverse reaction Nasal and Sinus Flushing: e-mail:[email protected] " To remove accumulated mucous and inflammatory material in the upper Adverse reactions may also be reported to the FDA/CVM at 1-888-FDA-VETS or respiratory tract, syringe into the nasal and sinus cavities (consisting of the http://www.fda.gov/AnimalVeterinary/SafetyHealth NOT APPROVED BY THE FDA external nares, operculum, nasal concha, infraorbital sinus and choanal slit) Legally marketed as an FDA Indexed Product under MIF 900-007. Extra-label use is prohibited. with the animal’s head down and mouth open to avoid aspiration and allow It is a violation of Federal law to use this product in a manner other than as directed on the labeling. drainage out of the oral cavity. This treatment should be repeated daily for 10- 14 days until the signs of illness resolve. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Evaluating Disinfectants for Use Against the COVID-19 Virus
    When it comes to choosing a disinfectant to combat the COVID-19 virus, research and health authorities suggest not all disinfectants are equally effective. The difference is in their active ingredient(s). HEALTH CANADA AND U.S. EPA ASSESSMENTS The work to evaluate disinfectants perhaps best starts with lists of approved disinfectants compiled by government health authorities. Health Canada has compiled a list of 85 hard surface disinfectant products (as of March 20, 2020) that meet their requirements for disinfection of emerging pathogens, including the virus that causes COVID-19. It can be accessed here. You can wade through the entire list. But if you locate the Drug Identification Number (DIN) on the disinfectant product label or the safety data sheet (SDS), then you can use the search function to quickly see if the product meets Health Canada requirements. A second list, updated on March 19, 2020, provides 287 products that meet the U.S. Environmental Protection Agency’s (EPA) criteria for use against SARS-CoV-2, the novel coronavirus that causes the disease COVID-19. This list can be found here. Like the Health Canada list, you can wade through this one too. However, to best use this list, you should locate the U.S. EPA registration number on the product label or SDS, and use that number to search the list. The U.S. EPA registration number of a product consists of two sets of numbers separated by a hyphen. The first set of numbers refers to the company identification number, and the second set of numbers following the hyphen represents the product number.
    [Show full text]
  • Effect of Polyhexamethylene Biguanide in Combination with Undecylenamidopropyl Betaine Or Pslg on Biofilm Clearance
    International Journal of Molecular Sciences Article Effect of Polyhexamethylene Biguanide in Combination with Undecylenamidopropyl Betaine or PslG on Biofilm Clearance Yaqian Zheng 1,2,†, Di Wang 1,† and Luyan Z. Ma 1,3,* 1 State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; [email protected] (Y.Z.); [email protected] (D.W.) 2 College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China 3 Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, China * Correspondence: [email protected]; Tel.: +86-10-64807437 † These authors have contributed equally to this work. Abstract: Hospital-acquired infection is a great challenge for clinical treatment due to pathogens’ biofilm formation and their antibiotic resistance. Here, we investigate the effect of antiseptic agent polyhexamethylene biguanide (PHMB) and undecylenamidopropyl betaine (UB) against biofilms of four pathogens that are often found in hospitals, including Gram-negative bacteria Pseudomonas aeruginosa and Escherichia coli, Gram-positive bacteria Staphylococcus aureus, and pathogenic fungus, Candida albicans. We show that 0.02% PHMB, which is 10-fold lower than the concentration of commercial products, has a strong inhibitory effect on the growth, initial attachment, and biofilm formation of all tested pathogens. PHMB can also disrupt the preformed biofilms of these pathogens. In contrast, 0.1% UB exhibits a mild inhibitory effect on biofilm formation of the four pathogens. This concentration inhibits the growth of S. aureus and C. albicans yet has no growth effect on P. aeruginosa or E. coli. UB only slightly enhances the anti-biofilm efficacy of PHMB on P.
    [Show full text]
  • FDA-2015-N-0101; and FDA-2016-N-0124
    DE PARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 November 18, 2020 Docket Nos. FDA-1975-N-0012; FDA-2015-N-0101; and FDA-2016-N-0124 The American Cleaning Institute Attention: James Kim, PhD Vice President, Science and Regulatory Affairs 1401 H Street, N.W. Suite 700 Washington, D.C. 20005 Re: Benzalkonium Chloride, Benzethonium Chloride, Chloroxylenol, Ethanol, and Povidone-Iodine Dear Dr. Kim: This letter responds to The American Cleaning Institute’s (ACI’s) July 14, 2020 communication regarding the deferral from final rulemaking under the over-the-counter (OTC) Drug Review on benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, and povidone-iodine for use in nonprescription (often referred to as over-the-counter or OTC) consumer antiseptic wash, health care antiseptic, and consumer antiseptic rub drug products. In March 2016, FDA issued letters granting requests to defer three active ingredients— benzalkonium chloride, benzethonium chloride, and chloroxylenol—from inclusion in the final rulemaking for the December 2013 proposed rule for OTC consumer antiseptic washes (78 FR 76444). Similarly, in January 2017, FDA issued letters granting requests to defer six active ingredients—benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, povidone- iodine, and isopropyl alcohol—from inclusion in the final rulemaking for the May 2015 proposed rule for OTC health care antiseptics (80 FR 25166). In October 2017, FDA issued letters granting requests to defer three active
    [Show full text]
  • Which Disinfectants Work Best Against C. Difficile?
    Science at Your Doorstep WHICH DISINFECTANTS WORK BEST AGAINST C. DIFFICILE? Summary: In healthcare facilities, Clostridium difficile infections spread by transmission of bacterial spores. Appropriate sporicidal disinfectants are needed to prevent development of clusters and outbreaks. In this study, researchers in The Netherlands compared the effectiveness of 4 different disinfectant classes on killing distinctive C. difficile spores. They published their results in the respected journal, Antimicrobial Resistance & Infection Control. Hydrogen peroxide disinfectant wipes showed the highest bactericidal activity. Publication Description: According to the study, a dilution of sodium hypochlorite (chlorine bleach) has historically been used in hospitals to disinfect areas contaminated with C. difficile spores. But the authors state that “hypochlorite has to be used in excessive concentrations to be effective, thereby increasing its toxic and corrosive properties.” So the authors searched for alternative disinfectant types to eliminate C. difficile spores. The 4 different disinfectant compounds tested were: 1. Glucoprotamin 2. Hydrogen peroxide 3. Ethanol/propane/amino propyl glycine 4. Didecyldimonium chloride/benzalkonium chloride/biguanide (quat) Tiles were contaminated with a solution containing 5x106 CFU/ml spores of C. difficile. The tiles were left to dry for an hour and then wiped or sprayed with one of the sprays or wipes as intended by the manufacturers. After 5 minutes, microbiological cultures were performed. Conclusion: The authors concluded that for each active ingredient, the wipes performed better than the sprays. In general, impregnated cleaning/disinfection wipes performed better than ready-to-use sprays. Wipes with hydrogen peroxide showed the highest bactericidal activity. Reference: See article at: Antimicrobial Resistance & Infection Control; Volume 6, No.
    [Show full text]
  • Clincal Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208288Orig1s000 CLINICAL REVIEW(S) Division Director Review NDA 208288 Chlorhexidine gluconate/isopropyl alcohol Summary Review for Regulatory Action Date September 1, 2017 Theresa M. Michele, MD From Director, Division of Nonprescription Drug Products Subject Division Director Summary Review NDA/BLA # 208288 Applicant Name 3M Health Care Business Date of Submission March 3, 2017 PDUFA Goal Date September 3, 2017 SoluPrep™ Film-Forming Sterile Solution / 2%w/v Proprietary Name / chlorhexidine gluconate and 70% v/v isopropyl Established (USAN) Name alcohol Dosage Forms / Route of Surgical solution Administration / Strength Patient Preoperative Skin Preparation (adults and pediatric patients ≥ 2 months of age) Proposed Indication(s) • For preparation of the skin prior to surgery • Helps reduce bacteria that potentially can cause skin infection Recommended Regulatory Complete response Action Material Reviewed/Consulted OND Action Package, including: Names of discipline reviewers Medical Officer Review--DNDP Teresa Podruchny/Francis Becker Statistical Review Joo-Yeon Lee/Rima Izem Pharmacology Toxicology Review Charlie Thompson/Jane Sohn CMC Review/OBP Review Elise Luong/Maria Cruz-Fisher/Erika Pfeiler/ Swapan De Clinical Microbiology Review Michelle Jackson Clinical Pharmacology Review Sojeong Yi/Dennis Bashaw CDTL Review Francis Becker OSE/DMEPA Grace Jones/Chi-Ming Tu RPM DNDP Lara Akinsanya CDTL=Cross-Discipline Team Leader DMEPA=Division of Medication Error Prevention and Analysis
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • In Vitro Evaluation of Polihexanide, Octenidine and Naclo/Hclo-Based Antiseptics Against Biofilm Formed by Wound Pathogens
    membranes Article In Vitro Evaluation of Polihexanide, Octenidine and NaClO/HClO-Based Antiseptics against Biofilm Formed by Wound Pathogens Grzegorz Krasowski 1, Adam Junka 2,3,* , Justyna Paleczny 2, Joanna Czajkowska 3, Elzbieta˙ Makomaska-Szaroszyk 4, Grzegorz Chodaczek 5, Michał Majkowski 5, Paweł Migdał 6, Karol Fijałkowski 7 , Beata Kowalska-Krochmal 2 and Marzenna Bartoszewicz 2 1 Nutrikon, KCZ Surgical Ward, 47-300 Krapkowice, Poland; [email protected] 2 Department of Pharmaceutical Microbiology and Parasitology, Faculty of Pharmacy, Wrocław Medical University, 50-556 Wrocław, Poland; [email protected] (J.P.); [email protected] (B.K.-K.); [email protected] (M.B.) 3 Laboratory of Microbiology, Łukasiewicz Research Network—PORT Polish Center for Technology Development, 54-066 Wrocław, Poland; [email protected] 4 Faculty of Medicine, Lazarski University, 02-662 Warszawa, Poland; [email protected] 5 Bioimaging Laboratory, Łukasiewicz Research Network—PORT Polish Center for Technology Development, 54-066 Wrocław, Poland; [email protected] (G.C.); [email protected] (M.M.) 6 Department of Environment Hygiene and Animal Welfare, Wroclaw University of Environmental and Life Sciences, 51-630 Wrocław, Poland; [email protected] 7 Department of Microbiology and Biotechnology, Faculty of Biotechnology and Animal Husbandry, West Pomeranian University of Technology, 70-311 Szczecin, Poland; karol.fi[email protected] * Correspondence: [email protected]; Tel.: +48-71-784-06-75 Citation: Krasowski, G.; Junka, A.; Paleczny, J.; Czajkowska, J.; Makomaska-Szaroszyk, E.; Abstract: Chronic wounds complicated with biofilm formed by pathogens remain one of the most Chodaczek, G.; Majkowski, M.; significant challenges of contemporary medicine.
    [Show full text]
  • Polyhexamethylene Biguanide (Mn = 1600; PDI =1.8) (PHMB)
    Regulation (EU) No 528/2012 concerning the making available on the market and use of biocidal products Evaluation of active substances Assessment Report Polyhexamethylene biguanide (Mn = 1600; PDI =1.8) (PHMB) Product-type 2: Disinfectants and algaecides not intended for direct application to humans or animals June 2015 France Polyhexamethylene biguanide Product-type 2 June 2015 (Mn = 1600; PDI =1.8) (PHMB) TABLE OF CONTENTS 1 STATEMENT OF SUBJECT MATTER AND PURPOSE .................................... 4 1.1 Procedure followed ------------------------------------------------------- 4 1.2 Purpose of the assessment ---------------------------------------------- 4 2 OVERALL SUMMARY AND CONCLUSIONS ................................................. 6 2.1 General substance information / General product information ----- 6 2.1.1 Identity, Physico-chemical properties & Methods of analysis of the active substance ---------------------------------------------------------------------------------------------------------------------- 6 2.1.1.1 Identity .................................................................................... 6 2.1.1.2 Physico-chemical properties ........................................................ 9 2.1.1.3 Methods of analysis .................................................................... 9 2.1.2 Identity, Physico-chemical properties & Methods of analysis of the biocidal product 10 2.1.2.1 Identity ................................................................................... 10 2.1.2.2 Physico-chemical properties
    [Show full text]
  • Release of Antimicrobial Agents from Glass Ionomer Cements
    Y T E I C O S L BALKAN JOURNAL OF STOMATOLOGY A ISSN 1107 - 1141 IC G LO TO STOMA Release of Antimicrobial Agents from Glass Ionomer Cements SUMMARY Aleksandar Dimkov, Elizabeta Gjorgievska, The aim of this study was to determine the level of antimicrobial Aleksandar Fildishevski agents Benzalkonium Chloride and Cetylpyridinium Chloride released Faculty of Dentistry, Clinic for Pediatric and from ChemFlex, a conventional glass ionomer cement (GIC). The main null Preventive Dentistry, Skopje, FYROM hypothesis tested was that there is no release of antimicrobial agents into the surrounding medium. 3 groups of the conventional ChemFlex GIC of 5 samples each, with Benzalconium Chloride and CPC incorporated, were prepared - each group with a different percentage of the agents (1%, 2%, and 3%). The determination of the quantity of the antimicrobial agents was done by an UV- Spectrophotometer. The measurements were performed at 11 successive time intervals. The results of the statistical analysis point out that it is possible to incorporate these antimicrobial agents in conventional GIC, especially when the added percentage of the antimicrobial agents is 3%. ORIGINAL PAPERS (OP) Keywords: GIC; Antimicrobial Agents; UV-Spectrophotometry Balk J Stom, 2012; 16:84-89 Introduction application9. There are several studies dealing with the effect of incorporating chlorhexidine in different Because of the relatively frequent occurrence of concentrations and its combinations in GIC to improve recurrent caries after a restorative treatment, and because their antimicrobial properties10-14. of the huge number of cariogenic microorganisms There are only a few data in the literature referring existing in the oral cavity, which present a potential to the incorporation and release of other antimicrobial risk factor regarding the development of new carious components in GIC.
    [Show full text]
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).
    [Show full text]
  • Chronic Venous Ulcers: a Comparative Effectiveness Review of Treatment Modalities Comparative Effectiveness Review Number 127
    Comparative Effectiveness Review Number 127 Chronic Venous Ulcers: A Comparative Effectiveness Review of Treatment Modalities Comparative Effectiveness Review Number 127 Chronic Venous Ulcers: A Comparative Effectiveness Review of Treatment Modalities Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10061-I Prepared by: Johns Hopkins University Evidence-based Practice Center Baltimore, MD Investigators Jonathan Zenilman, M.D. M. Frances Valle, D.N.P., M.S. Mahmoud B. Malas, M.D., M.H.S. Nisa Maruthur, M.D., M.H.S. Umair Qazi, M.P.H. Yong Suh, M.B.A., M.Sc. Lisa M. Wilson, Sc.M. Elisabeth B. Haberl, B.A. Eric B. Bass, M.D., M.P.H. Gerald Lazarus, M.D. AHRQ Publication No. 13(14)-EHC121-EF December 2013 Erratum January 2014 This report is based on research conducted by the Johns Hopkins University Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10061-I). The findings and conclusions in this document are those of the author(s), who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services.
    [Show full text]